Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
机构:[1]Department of Oncology, Qinhuai Medical Area, Eastern Theater General Hospital of PLA China, Nanjing, China.[2]Department of Oncology, Tongji University Shanghai East Hospital, Shanghai, China. lijin@csco.org.cn.[3]Department of Abdominal Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.浙江省肿瘤医院[4]Department of Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.[5]Department of Hematology and Oncology, Taizhou First People's Hospital, Taizhou, China.[6]Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.华中科技大学同济医学院附属同济医院[7]Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.[8]Department of Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.[9]Department of Oncology, The Third Xiangya Hospital of Central South University, Changsha, China.[10]Chemotherapeutic Department, Zhongshan City People's Hospital, Zhongshan, China.[11]Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.临床科室肿瘤内科河北医科大学第四医院[12]Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.重庆医科大学附属第一医院[13]Cancer Center, The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai, China.[14]Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.[15]Department of Gastrointestinal Oncology, The First People's Hospital of Foshan, Foshan, China.[16]Shanghai Henlius Biotech, Inc., Shanghai, China.
第一作者机构:[1]Department of Oncology, Qinhuai Medical Area, Eastern Theater General Hospital of PLA China, Nanjing, China.
推荐引用方式(GB/T 7714):
Qin Shukui,Li Jin,Zhong Haijun,et al.Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial[J].British journal of cancer.2022,doi:10.1038/s41416-022-02043-7.
APA:
Qin Shukui,Li Jin,Zhong Haijun,Jin Chuan,Chen Lili...&.(2022).Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial.British journal of cancer,,
MLA:
Qin Shukui,et al."Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial".British journal of cancer .(2022)